Results 341 to 350 of about 146,874 (392)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2023
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ...
C. Vogel +12 more
semanticscholar +1 more source
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ...
C. Vogel +12 more
semanticscholar +1 more source
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients [PDF]
Cancer Cell, 2004 Keng-Hsueh Lan +2 more
exaly +2 more sources
Cancer Research, 2005 To the Editor: We read with interest the article by Adams et al. [(1)][1], which describes the efficacy of an yttrium-90-labeled anti-HER2 diabody in a mouse xenograft model of HER2-positive breast cancer.
Charles L. Vogel +2 more
openaire +2 more sources
Physicochemical and Functional Characterization of trastuzumab-dkst, a Trastuzumab Biosimilar
Future Medicinal Chemistry, 2021Aims: Preclinical comparative similarity studies of trastuzumab-dkst, a Herceptin® biosimilar, are reported. Materials & methods: Primary sequence and higher order structure and pharmacological mechanisms of action were compared using multiple techniques. Pharmacokinetics and repeat-dose toxicity were assessed in cynomolgus monkeys.
Parag Goyal +19 more
openaire +2 more sources
BioDrugs, 1999
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours. The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
Caroline M. Perry, Lynda R. Wiseman
openaire +5 more sources
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours. The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
Caroline M. Perry, Lynda R. Wiseman
openaire +5 more sources
MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases
Science Translational Medicine, 2021Description MRgFUS is a safe, noninvasive method to deliver spatially targeted monoclonal antibody across the BBB in patients with brain tumors. Focusing on delivery Drug delivery to the brain is hampered by the presence of the blood-brain barrier (BBB).
Y. Meng +16 more
semanticscholar +1 more source
Environmental Toxicology, 2022
HER2‐positive breast cancer is an aggressive subtype of breast cancer, characterized by high malignancy and poor prognosis. Trastuzumab, the first HER2‐targeted monoclonal antibody therapy, has a crucial role in a curative setting in HER2‐positive breast
Shengting Wang +4 more
semanticscholar +1 more source
HER2‐positive breast cancer is an aggressive subtype of breast cancer, characterized by high malignancy and poor prognosis. Trastuzumab, the first HER2‐targeted monoclonal antibody therapy, has a crucial role in a curative setting in HER2‐positive breast
Shengting Wang +4 more
semanticscholar +1 more source
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
New England Journal of MedicineBACKGROUND Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of ...
A. Bardia +18 more
semanticscholar +1 more source